Table 1.

Baseline characteristics in men presented as endothelin-1 quintiles

Men	Q1 n = 131	Q2 n = 131	Q3 n = 131	Q4 n = 131	Q5 n = 131
Age (years)	50 ± 12	49 ± 12	48 ± 12	50 ± 13	50 ± 11
eGFR < 60% (n)	2% (2)	2% (3)	0.00% (0)	2% (3)	0% (0)
eGFR < 60% (n) + 9,7 yr	10% (13)	8% (10)	11% (14)	6% (7)	6% (7)
eGFR mean	89 ± 15	91 ± 17	89 ± 13	92 ± 15	91 ± 15
eGFR mean + 9.7 yr	80 ± 14	82 ± 17	80 ± 15	82 ± 13	82 ± 14
Diabetes (%)	6.1%	3.8%	3.8%	3.8%	9.2%
Diabetes (%) + 9,7 yr	13.0%	9.9%	11.5%	10.7%	15.3%
Hypertension (%)	13.7%	20.6%	13.7%	16.8%	13.0%
Hypertension (%) + 9,7 yr	29.0%	35.1%	28.2%	31.3%	29.8%
Smoking (%)	18.30%	6.90%	14.50%	13.70%	16.00%
LDL	3.3 ± 0.8	3.3 ± 0.8	3.3 ± 0.9	3.5 ± 1.0	3.5 ± 0.9
LDL + 9,7 yr	3.4 ± 1.0	3.4 ± 0.9	3.6 ± 0.9	3.6 ± 1.1	3.5 ± 0.9
WHR	0.94 ± 0.06	0.94 ± 0.06	0.94 ± 0.06	0.94 ± 0.06	0.94 ± 0.06
HOMA-IR	1.6 ± 1.1	1.5 ± 1.1	1.5 ± 0.9	1.6 ± 1.3	1.9 ± 1.4*
hS-CRP	1.9 ± 2.0	3.3 ± 13.5	2.7 ± 7.8	2.4 ± 4.0	1.9 ± 1.8
Low LTPA	8.40%	6.10%	9.20%	6.10%	9.20%

Means ± SD, and frequency/percentages of clinical variables between endothelin-1 quintiles. HOMA-IR: homeostatic model assessment of insulin resistance; WHR Waist/hip ratio, LDL Low-density lipoprotein, hS-CRP High sensitive C-reactive protein, Low LTPA Low leisure time physical activity

Range of quintiles [ET-1] (pg/mL) 1: 0.02–1.25, 2: 1.26–1.97, 3: 1.98–2.61, 4: 2.62–3.35, 5: 3.36–6.24

* = P-value < 0.05